Abstract
Inclusion body myopathy (IBM) associated with pagets disease of the bone (PDB) and fronto-temporal dementia (FTD) or IBMPFD, is a rare multisystem degenerative disorder due to mutations in valosin containing protein (VCP). VCP is a ubiquitously expressed protein that facilitates the degradation of proteins via the ubiquitin proteasome and autophagy pathways. Affected brain and muscle tissue in IBMPFD have ubiquitinated and TAR DNA binding protein- 43 (TDP-43) inclusions. In skeletal muscle, this pathology is consistent with IBM. While in the CNS, IBMPFD is a frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) subtype. Recent studies suggest that IBMPFD mutations in VCP disrupt its function in protein degradation. This review will explore the clinical phenotype and pathology of IBMPFD with an emphasis on central nervous system degeneration. In addition, we will discuss the current understanding regarding VCPs function in terminally differentiated tissue and how disease associated mutations result in both myo- and neurodegeneration.
Keywords: VCP, IBMPFD, FTD, ubiquitin, TDP-43, neurodegeneration, PDB, dilated cardiomyopathy, hepatic steatosis, phenotypic components, missense mutation, early psychotic features, IBM, FDG-PET
Current Alzheimer Research
Title: Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis
Volume: 8 Issue: 3
Author(s): C. C. Weihl
Affiliation:
Keywords: VCP, IBMPFD, FTD, ubiquitin, TDP-43, neurodegeneration, PDB, dilated cardiomyopathy, hepatic steatosis, phenotypic components, missense mutation, early psychotic features, IBM, FDG-PET
Abstract: Inclusion body myopathy (IBM) associated with pagets disease of the bone (PDB) and fronto-temporal dementia (FTD) or IBMPFD, is a rare multisystem degenerative disorder due to mutations in valosin containing protein (VCP). VCP is a ubiquitously expressed protein that facilitates the degradation of proteins via the ubiquitin proteasome and autophagy pathways. Affected brain and muscle tissue in IBMPFD have ubiquitinated and TAR DNA binding protein- 43 (TDP-43) inclusions. In skeletal muscle, this pathology is consistent with IBM. While in the CNS, IBMPFD is a frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U) subtype. Recent studies suggest that IBMPFD mutations in VCP disrupt its function in protein degradation. This review will explore the clinical phenotype and pathology of IBMPFD with an emphasis on central nervous system degeneration. In addition, we will discuss the current understanding regarding VCPs function in terminally differentiated tissue and how disease associated mutations result in both myo- and neurodegeneration.
Export Options
About this article
Cite this article as:
C. Weihl C., Valosin Containing Protein Associated Fronto-Temporal Lobar Degeneration:Clinical Presentation, Pathologic Features and Pathogenesis, Current Alzheimer Research 2011; 8 (3) . https://dx.doi.org/10.2174/156720511795563773
DOI https://dx.doi.org/10.2174/156720511795563773 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Cholinesterases Inhibitors for Alzheimers Disease Treatment
Current Medicinal Chemistry Recent Progress in Pharmacological and Non-Pharmacological Treatment Options of Major Depression
Current Pharmaceutical Design Editorial [Hot Topic: Frontotemporal Lobar Degeneration and Related Disorders (Guest Editor: Barbara Borroni)]
Current Alzheimer Research State-of-the-Art Lentiviral Vectors for Research Use: Risk Assessment and Biosafety Recommendations
Current Gene Therapy Predicted Fold for the Abri Amyloid Subunit: A Model for Amyloidogenesis in Familial British Dementia
Protein & Peptide Letters Targeting the Alpha 7 Nicotinic Acetylcholine Receptor to Reduce Amyloid Accumulation in Alzheimers Disease Pyramidal Neurons
Current Pharmaceutical Design Enhanced α-Synuclein Expression in Human Neurodegenerative Diseases: Pathogenetic and Therapeutic Implications
Current Protein & Peptide Science Treatment Options in Alzheimer´s Disease: The GABA Story
Current Pharmaceutical Design Isotyping the Human TOMM40 Variable-Length Polymorphism by Gene Amplification and Restriction Digest
Current Alzheimer Research PLA2G6 Mutations and Other Rare Causes of Neurodegeneration with Brain Iron Accumulation
Current Drug Targets Tryptophan Catabolites and Their Impact on Multiple Sclerosis Progression
Current Pharmaceutical Design Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry The Long Non-Coding RNAs in Neurodegenerative Diseases: Novel Mechanisms of Pathogenesis
Current Alzheimer Research Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Editorial: Effect of Statins on Rates of Long-Term Cardiovascular Events and Restenosis Following Carotid Endarterectomy
Current Vascular Pharmacology Current Status and Perspectives in Ceramide-Targeting Molecular Medicine
Current Pharmaceutical Design Editorial: Brain Imaging and Automatic Analysis in Neurological and Psychiatric Diseases – Part II
CNS & Neurological Disorders - Drug Targets Obstructive Sleep Apnea and Stroke
Current Respiratory Medicine Reviews Domperidone and Long QT Syndrome
Current Drug Safety Migraine and Obesity: Is There a Relationship? A Systematic Review and Meta-Analysis of Observational Studies
CNS & Neurological Disorders - Drug Targets